# RELAY (NCT02411448)

> A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02411448
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Metastatic Non-Small Cell Lung Cancer
- Interventions: Ramucirumab; Placebo; Erlotinib; Gefitinib; Osimertinib
- Enrollment: 545
- Primary outcome: Part B: Progression Free Survival (PFS)
- Primary outcome: Number of Participants With Treatment-Emergent Adverse Events

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=relay-nct02411448